Pathways to Silencing Psoriasis: Remission or Cure?

Date: Friday 20 September 2019
Time: 13.00-14.30
Room: tba

Learning objectives

After this session, participants should be able to:
• Recognize the clinical implications of the pathophysiology of psoriasis and its comorbidities
• Devise strategies for treatment individualization and optimization based on the patient needs, genetic predisposition, and pharmacoeconomic considerations
• Critique the role of disease modification and hypothesize how treatment optimization strategies could be utilized for optimal long-term patient outcomes


13.00-13.05 Welcome and introduction
Jo Lambert (Ghent, Belgium)

 13.05-13.25 The role of IL-23 in the pathogenesis of psoriasis – a common pathway in immune-mediated inflammatory diseases
Jörg Prinz (Munich, Germany)

13.25-13.45 Optimizing psoriasis care of patients with comorbidity
Jo Lambert (Ghent, Belgium)

13.45-14.05 Future of psoriasis: can lasting improvement be achieved in psoriasis care?
Carle Paul (Toulouse, France)

14.05-14.25 Interactive Q&A session

14.25-14.30 Concluding remarks and close of the meeting
Jörg Prinz (Munich, Germany)